Development of radiotracers for oncology - The interface with pharmacology

British Journal of Pharmacology

Volumn 163, Issue 8, 2011, Pages 1565-1585

  Sharma, Rohini ^a,b   Aboagye, Eric ^a  

^a Imperial College London Hammersmith Campus   (United Kingdom)

^b Imperial College London Hammersmith Campus   (United Kingdom)

Author keywords

drug development; positron emission tomography (PET); radioisotope; radiopharmaceutical

Indexed keywords

3' FLUOROTHYMIDINE F 18; BROMINE 76; CARBON 11; CARBON 13; CHOLINE C 11; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; COPPER 64; CYCLOPHOSPHAMIDE; DOXORUBICIN; ERLOTINIB; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GALLIUM 68; GATAPARSEN; GEFITINIB; IMATINIB; IODINE 124; METHIONINE C 11; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NITROGEN 13; OXYGEN 15; RADIOLIGAND; RAPAMYCIN; TRACER; TRASTUZUMAB; UNINDEXED DRUG; YTTRIUM 86;

AMINO ACID SEQUENCE; ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER SURVIVAL; CARCINOGENICITY; CARDIOTOXICITY; CELL PROLIFERATION; CHEMICAL STRUCTURE; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG LABELING; DRUG METABOLISM; DRUG MICRODOSE; DRUG PURITY; DRUG RESPONSE; DRUG SYNTHESIS; ESOPHAGUS CANCER; FIBROSARCOMA; GASTROINTESTINAL STROMAL TUMOR; GENOTOXICITY; GLIOBLASTOMA; GLUCOSE UTILIZATION; GOOD MANUFACTURING PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOGENICITY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MASS SPECTROMETRY; MELANOMA; MULTICELLULAR SPHEROID; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOLOGY; ONE POT SYNTHESIS; OVERALL SURVIVAL; PHARMACOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; QUALITY CONTROL; RADIOACTIVITY; RADIOCHEMISTRY; REVIEW; TOXICITY TESTING; TOXICOKINETICS; TUMOR SPHEROID;

ANTINEOPLASTIC AGENTS; DIAGNOSTIC IMAGING; DRUG DESIGN; GUIDELINES AS TOPIC; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RADIOISOTOPES; RADIOLIGAND ASSAY;

EID: 79960922227     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01160.x     Document Type: Review

References (147)

1. Ahmed FY, Johnston SJ, Cassidy J, O'Kelly T, Binnie N, Murray GI, et al,. (1999). Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors. J Clin Oncol 17: 2439-2445. (Pubitemid 29368243)
2. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, et al,. (2006). Early detection of chemoradioresponse in esophageal carcinoma by 3′-deoxy-3′-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res 12: 4590-4597. (Pubitemid 44297809)
3. Bading JR, Shields AF, (2008). Imaging of cell proliferation: status and prospects. J Nucl Med 49 (Suppl. 2): 64S-80S. (Pubitemid 351948037)
4. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al,. (2003). 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63: 3791-3798. (Pubitemid 36793068)
5. Barthel H, Perumal M, Latigo J, He Q, Brady F, Luthra SK, et al,. (2005). The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 32: 257-263. (Pubitemid 40562116)
6. Barwick T, Bencherif B, Mountz JM, Avril N, (2009). Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Nucl Med Commun 30: 908-917.
7. Bates RC, Edwards NS, Yates JD, (2000). Spheroids and cell survival. Crit Rev Oncol Hematol 36: 61-74.
8. Been LB, Hoekstra HJ, Suurmeijer AJ, Jager PL, van der Laan BF, Elsinga PH, (2009). [18F]FLT-PET and [18F]FDG-Pet in the evaluation of radiotherapy for laryngeal cancer. Oral Oncol 45: e211-e215.
9. Bergstrom M, Grahnen A, Langstrom B, (2003). Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 59: 357-366. (Pubitemid 37214939)
10. Blankenberg FG, (2008). In vivo detection of apoptosis. J Nucl Med 49 (Suppl. 2): 81S-95S. (Pubitemid 351948038)
11. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al,. (1998). In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A 95: 6349-6354. (Pubitemid 28249015)
12. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al,. (1999). Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med 40: 184-191. (Pubitemid 29044190)
13. Brepoels L, Stroobants S, Verhoef G, De Groot T, Mortelmans L, De Wolf-Peeters C, (2009). (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. J Nucl Med 50: 1102-1109.
14. Buck AK, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D, et al,. (2007). Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging 34: 1775-1782. (Pubitemid 47599048)
15. Burton C, Ell P, Linch D, (2004). The role of PET imaging in lymphoma. Br J Haematol 126: 772-784. (Pubitemid 39273817)
16. Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X, (2006). In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res 66: 9673-9681. (Pubitemid 44623667)
17. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al,. (2007). Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25: 4714-4721. (Pubitemid 350086472)
18. CHMP (C.f.M.P.f.H.U.) (2004). Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with A Single Microdose., Agency EM, (ed.) European Medicines Agency: London.
19. Cohen A, Shirvan A, Levin G, Grimberg H, Reshef A, Ziv I, (2009). From the Gla domain to a novel small-molecule detector of apoptosis. Cell Res 19: 625-637.
20. Collingridge DR, Carroll VA, Glaser M, Aboagye EO, Osman S, Hutchinson OC, et al,. (2002). The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 62: 5912-5919. (Pubitemid 35204754)
21. Collins JM, (2003). Functional imaging in phase I studies: decorations or decision making? J Clin Oncol 21: 2807-2809. (Pubitemid 46621827)
22. Contractor KB, Aboagye EO, (2009). Monitoring predominantly cytostatic treatment response with 18F-FDG PET. J Nucl Med 50 (Suppl. 1): 97S-105S.
23. Di Fabio F, Pinto C, Rojas Llimpe FL, Fanti S, Castellucci P, Longobardi C, et al,. (2007). The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer 10: 221-227. (Pubitemid 350308171)
24. Dimasi JA, (2001). Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 69: 297-307.
25. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Irngartinger G, Oberdorfer F, et al,. (1998). Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 39: 465-473. (Pubitemid 28136845)
26. Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, et al,. (2002). Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 29: 1462-1469. (Pubitemid 35232048)
27. Dubessy C, Merlin JM, Marchal C, Guillemin F, (2000). Spheroids in radiobiology and photodynamic therapy. Crit Rev Oncol Hematol 36: 179-192.
28. EANM Radiopharmacy Committee (2007). Guidelines on Current Good Radiopharmacy Practice (cGRPP) in the Preparation of Radiopharmaceuticals.
29. Ebenhan T, Honer M, Ametamey SM, Schubiger PA, Becquet M, Ferretti S, et al,. (2009). Comparison of [18F]-tracers in various experimental tumor models by PET imaging and identification of an early response biomarker for the novel microtubule stabilizer patupilone. Mol Imaging Biol 11: 308-321.
30. EMEA (2009). Questions & Answers on the CHMP Guideline on the Limits of Genotoxic Impurities (EMA/CHMP/SWP/431994/2007/Revision 2), Agency TEME, (ed.) London,.
31. Everitt S, Hicks RJ, Ball D, Kron T, Schneider-Kolsky M, Walter T, et al,. (2009). Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 75: 1098-1104.
32. FDA (2004). Innovation or stagnation: challenge and opportunity on the critical path to new medical products.
33. FDA (2010). Critical Path 2010 Update. U.S. Department of Health & Human Services.
34. Fowler JS, MacGregor RR, Wolf AP, Farrell AA, Karlstrom KI, Ruth TJ, (1981). A shielded synthesis system for production of 2-deoxy-2-[18F]fluoro-D- glucose. J Nucl Med 22: 376-380. (Pubitemid 11143696)
35. Fracasso G, Colombatti M, (2000). Effect of therapeutic macromolecules in spheroids. Crit Rev Oncol Hematol 36: 159-178.
36. Galldiks N, Kracht LW, Burghaus L, Ullrich RT, Backes H, Brunn A, et al,. (2010). Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging 9: 40-46.
37. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME, (2001). A tabulated summary of the FDG PET literature. J Nucl Med 42: 1S-93S. (Pubitemid 32423895)
38. Ginos JZ, Cooper AJ, Dhawan V, Lai JC, Strother SC, Alcock N, et al,. (1987). [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 28: 1844-1852. (Pubitemid 18017095)
39. Glaser M, Collingridge DR, Aboagye EO, Bouchier-Hayes L, Hutchinson OC, Martin SJ, et al,. (2003). Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl Radiat Isot 58: 55-62. (Pubitemid 35453947)
40. Glunde K, Jie C, Bhujwalla ZM, (2004). Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 64: 4270-4276. (Pubitemid 38802433)
41. Glunde K, Raman V, Mori N, Bhujwalla ZM, (2005). RNA interference- mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res 65: 11034-11043. (Pubitemid 41713374)
42. Graf N, Herrmann K, den Hollander J, Fend F, Schuster T, Wester HJ, et al,. (2008). Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol 10: 349-355.
43. Gray KR, Contractor KB, Kenny LM, Al-Nahhas A, Shousha S, Stebbing J, et al,. (2010). Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studies. Phys Med Biol 55: 695-709.
44. Grimberg H, Levin G, Shirvan A, Cohen A, Yogev-Falach M, Reshef A, et al,. (2009). Monitoring of tumour response to chemotherapy in vivo by a novel small-molecule detector of apoptosis. Apoptosis 14: 257-267.
45. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al,. (2005). [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106: 1376-1381. (Pubitemid 41129604)
46. Hamacher K, Coenen HH, Stocklin G, (1986). Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27: 235-238. (Pubitemid 17024868)
47. Hanahan D, Weinberg RA, (2000). The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
48. Hara T, Kosaka N, Kishi H, (1998). PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39: 990-995. (Pubitemid 28270113)
49. Harte RJ, Matthews JC, O'Reilly SM, Price PM, (1998). Sources of error in tissue and tumor measurements of 5-[18F]fluorouracil. J Nucl Med 39: 1370-1376.
50. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, et al,. (2001). Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61: 1781-1785. (Pubitemid 32691983)
51. Herrmann K, Wieder HA, Buck AK, Schoffel M, Krause BJ, Fend F, et al,. (2007). Early response assessment using 3′-deoxy-3′-[18F] fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 13: 3552-3558. (Pubitemid 46955115)
52. Hofstra L, Liem IH, Dumont EA, Boersma HH, van Heerde WL, Doevendans PA, et al,. (2000). Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 356: 209-212. (Pubitemid 30446976)
53. Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, et al,. (2007). CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 189: W324-W330.
54. Iwata R, Ido T, Takahashi T, Monma M, (1984). Automated synthesis system for productino of 2-deoxy-[18F]fluoro-D-glucose with computer control. Appl Radiat Isot 35: 445-454. (Pubitemid 14111717)
55. Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, et al,. (2002). Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94: 1484-1493. (Pubitemid 35251753)
56. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ, (2003). 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44: 32-38; discussion 38-39.
57. Kawada K, Murakami K, Sato T, Kojima Y, Ebi H, Mukai H, et al,. (2007). Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors. Jpn J Clin Oncol 37: 44-48. (Pubitemid 47090722)
58. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al,. (2005). Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11: 2785-2808. (Pubitemid 40525178)
59. Kenny LM, Vigushin DM, Al-Nahhas A, Osman S, Luthra SK, Shousha S, et al,. (2005). Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 65: 10104-10112. (Pubitemid 41541493)
60. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO, (2007). Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34: 1339-1347. (Pubitemid 47312585)
61. Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, et al,. (2008). Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med 49: 879-886. (Pubitemid 351793427)
62. Kenny LM, Contractor KB, Stebbing J, Al-Nahhas A, Palmieri C, Shousha S, et al,. (2009). Altered tissue 3′-deoxy-3′-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin Cancer Res 15: 6649-6657.
63. Kenny LM, Contractor KB, Hinz R, Stebbing J, Palmieri C, Jiang J, et al,. (2010). Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab. Clin Cancer Res 16: 4236-4245.
64. Kissel J, Brix G, Bellemann ME, Strauss LG, Dimitrakopoulou-Strauss A, Port R, et al,. (1997). Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 57: 3415-3423. (Pubitemid 27355486)
65. Krause BJ, Souvatzoglou M, Herrmann K, Weber AW, Schuster T, Buck AK, et al,. (2010). [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model. Eur J Nucl Med Mol Imaging 37: 1861-1868.
66. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R, (2004). The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 9: 273-285.
67. Kurdziel KA, Kiesewetter DO, Carson RE, Eckelman WC, Herscovitch P, (2003). Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. J Nucl Med 44: 1330-1339. (Pubitemid 39655194)
68. Lee JH, Rosen EL, Mankoff DA, (2009). The role of radiotracer imaging in the diagnosis and management of patients with breast cancer: part 1-overview, detection, and staging. J Nucl Med 50: 569-581.
69. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO, (2005). Early detection of tumor response to chemotherapy by 3′-deoxy-3′- [18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 65: 4202-4210. (Pubitemid 40775658)
70. Leyton J, Alao JP, Da Costa M, Stavropoulou AV, Latigo JR, Perumal M, et al,. (2006a). In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Cancer Res 66: 7621-7629. (Pubitemid 44289219)
71. Leyton J, Lockley M, Aerts JL, Baird SK, Aboagye EO, Lemoine NR, et al,. (2006b). Quantiflying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography imaging. Cancer Res 66: 9178-9185. (Pubitemid 44521138)
72. Leyton J, Smith G, Lees M, Perumal M, Nguyen QD, Aigbirhio FI, et al,. (2008). Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther 7: 3112-3121.
73. Leyton J, Smith G, Zhao Y, Perumal M, Nguyen QD, Robins E, et al,. (2009). [18F]fluoromethyl-[1,2-2H4]-choline: a novel radiotracer for imaging choline metabolism in tumors by positron emission tomography. Cancer Res 69: 7721-7728.
74. Marchetti S, Schellens JH, (2007). The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer 97: 577-581. (Pubitemid 47339894)
75. MHRA (2007). Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2007.
76. MHRA (2010). Applying to Conduct A Clinical Trial: Additional Information, Vol. 2010. Medicines and Healthcare products Regulatory Agency (MHRA).
77. Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U, Strauss LG, Stremmel W, (1998). 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 83: 245-253. (Pubitemid 28317803)
78. Molthoff CF, Klabbers BM, Berkhof J, Felten JT, van Gelder M, Windhorst AD, et al,. (2007). Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2′-deoxy-2′-[18F]fluoro-D- glucose (FDG) and 3′-[18F]fluoro-3′-deoxythymidine (FLT). Mol Imaging Biol 9: 340-347.
79. Monazzam A, Razifar P, Simonsson M, Qvarnstrom F, Josephsson R, Blomqvist C, et al,. (2006). Multicellular tumour spheroid as a model for evaluation of [18F]FDG as biomarker for breast cancer treatment monitoring. Cancer Cell Int 6: 6.
80. Monazzam A, Josephsson R, Blomqvist C, Carlsson J, Langstrom B, Bergstrom M, (2007). Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer. Breast Cancer Res 9: R45.
81. Monazzam A, Razifar P, Ide S, Rugaard Jensen M, Josephsson R, Blomqvist C, et al,. (2009). Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake. Nucl Med Biol 36: 335-342.
82. Mueller-Klieser W, (2000). Tumor biology and experimental therapeutics. Crit Rev Oncol Hematol 36: 123-139.
83. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G, (1995). Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 35: 69-89.
84. Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, et al,. (2007). In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48: 1313-1319. (Pubitemid 47242797)
85. Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO, (2009). Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A 106: 16375-16380.
86. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al,. (2001). Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421-1423. (Pubitemid 33055745)
87. Osman S, Rowlinson-Busza G, Luthra SK, Aboagye EO, Brown GD, Brady F, et al,. (2001). Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues. Cancer Res 61: 2935-2944. (Pubitemid 32691938)
88. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, et al,. (2006). Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24: 4692-4698. (Pubitemid 46646244)
89. Oyama N, Akino H, Suzuki Y, Kanamaru H, Ishida H, Tanase K, et al,. (2001). FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nuclear Med Commun 22: 963-969. (Pubitemid 32783446)
90. Pan MH, Huang SC, Liao YP, Schaue D, Wang CC, Stout DB, et al,. (2008). FLT-PET imaging of radiation responses in murine tumors. Mol Imaging Biol 10: 325-334
91. Pardo OE, Latigo J, Jeffery RE, Nye E, Poulsom R, Spencer-Dene B, et al,. (2009). The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 69: 8645-8651.
92. Perumal M, Pillai RG, Barthel H, Leyton J, Latigo JR, Forster M, et al,. (2006). Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 66: 8558-8564. (Pubitemid 44449169)
93. Pfannenberg C, Aschoff P, Dittmann H, Mayer F, Reischl G, von Weyhern C, et al,. (2010). PET/CT with 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors? J Nucl Med 51: 845-853.
94. Pillai RG, Forster M, Perumal M, Mitchell F, Leyton J, Aibgirhio FI, et al,. (2008). Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945. Cancer Res 68: 3827-3834.
95. Pimlott SL, (2005). Radiotracer development in psychiatry. Nucl Med Commun 26: 183-188. (Pubitemid 40411041)
96. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, et al,. (2006). Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8: 36-42. (Pubitemid 44201576)
97. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F, et al,. (2002). Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 296: 580-583.
98. Ramirez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Taron M, Ramirez de Molina V, Cejas P, et al,. (2007). Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol 8: 889-897. (Pubitemid 47488053)
99. Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al,. (2006). Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med 47: 1249-1254. (Pubitemid 47544875)
100. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, et al,. (2010). Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumad. J Nucl Med 51: 340-346.
101. Romer W, Hanauske AR, Ziegler S, Thodtmann R, Weber W, Fuchs C, et al,. (1998). Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 91: 4464-4471. (Pubitemid 28270292)
102. Rosenbaum SJ, Lind T, Antoch G, Bockisch A, (2006). False-positive FDG PET uptake-the role of PET/CT. Eur Radiol 16: 1054-1065.
103. Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, et al,. (2009). A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res 69: 120-127.
104. Rueger MA, Ameli M, Li H, Winkeler A, Rueckriem B, Vollmar S, et al,. (2010). [(18)F]FLT PET for non-invasive monitoring of early response to gene therapy in experimental gliomas. Mol Imaging Biol 13: 547-557.
105. Saleem A, Aboagye EO, Price PM, (2000a). In vivo monitoring of drugs using radiotracer techniques. Adv Drug Deliv Rev 41: 21-39. (Pubitemid 30122947)
106. Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV, et al,. (2000b). Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 355: 2125-2131. (Pubitemid 30364662)
107. Saleem A, Harte RJ, Matthews JC, Osman S, Brady F, Luthra SK, et al,. (2001). Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4- carboxamide in patients by positron emission tomography. J Clin Oncol 19: 1421-1429. (Pubitemid 32202549)
108. Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, et al,. (2003). Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 63: 2409-2415. (Pubitemid 36605177)
109. Saleem A, Aboagye EO, Matthews JC, Price PM, (2008). Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. Cancer Chemother Pharmacol 61: 865-873. (Pubitemid 351302041)
110. Saleem A, Ranson M, Callies S, Lahn M, Prenant C, Brown GD, et al,. (2009). Microdosing imaging pharmacokinetic (PK) study of the antisense oligonucleotide (ASO) to survivin (LY2181308) using positron emission tomography (PET): a novel paradigm in clinical drug development. J Clin Oncol 27: 15s (suppl; abstr 3578).
111. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, et al,. (2000). Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18: 1689-1695. (Pubitemid 30220547)
112. Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker HC, et al,. (2007). Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 34: 45-53. (Pubitemid 44885553)
113. Seitz U, Wagner M, Neumaier B, Wawra E, Glatting G, Leder G, et al,. (2002). Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F]fluoro-3′-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 29: 1174-1181. (Pubitemid 34985362)
114. Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, et al,. (2009). Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 15: 4712-4721.
115. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al,. (2006). Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47: 1059-1066. (Pubitemid 46939960)
116. Sherley JL, Kelly TJ, (1988). Regulation of human thymidine kinase during the cell cycle. J Biol Chem 263: 8350-8358.
117. Shibuya M, (2008). Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 41: 278-286. (Pubitemid 351656921)
118. Shields AF, Graham MM, Kozawa SM, Kozell LB, Link JM, Swenson ER, et al,. (1992). Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. J Nucl Med 33: 581-584.
119. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al,. (1998). Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4: 1334-1336. (Pubitemid 28512118)
120. Shreve PD, Anzai Y, Wahl RL, (1999). Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19: 61-77; quiz 150-151.
121. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al,. (2000). Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18: 1676-1688. (Pubitemid 30220546)
122. Smith G, Glaser M, Perumal M, Nguyen QD, Shan B, Arstad E, et al,. (2008). Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide. J Med Chem 51: 8057-8067.
123. Sohn HJ, Yang YJ, Ryu JS, Oh SJ, Im KC, Moon DH, et al,. (2008). [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 14: 7423-7429.
124. Solit DB, Santos E, Pratilas CA, Lobo J, Moroz M, Cai S, et al,. (2007). 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res 67: 11463-11469. (Pubitemid 350248575)
125. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al,. (2003). 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39: 2012-2020. (Pubitemid 37297757)
126. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P, (2008). Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17: 323-334.
127. Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK, Wahl RL, (2005). Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics 25: 1031-1043. (Pubitemid 41196938)
128. Sugiyama M, Sakahara H, Sato K, Harada N, Fukumoto D, Kakiuchi T, et al,. (2004). Evaluation of 3′-deoxy-3′-18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med 45: 1754-1758. (Pubitemid 47618487)
129. Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T, et al,. (2008). Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer 59: 203-210. (Pubitemid 351173409)
130. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH, (2010). 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 51: 866-874.
131. Tyler JL, Yamamoto YL, Diksic M, Theron J, Villemure JG, Worthington C, et al,. (1986). Pharmacokinetics of superselective intra-arterial and intravenous [11C]BCNU evaluated by PET. J Nucl Med 27: 775-780. (Pubitemid 17022664)
132. Ullrich RT, Zander T, Neumaier B, Koker M, Shimamura T, Waerzeggers Y, et al,. (2008). Early detection of erlotinib treatment response in NSCLC by 3′-deoxy-3′-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). Plos One 3: e3908.
133. Vallabhajosula S, (2007). (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 37: 400-419. (Pubitemid 47505221)
134. VanBrocklin HF, (2008). Radiopharmaceuticals for drug development: United States regulatory perspective. Current Radiopharmaceuticals 1: 2-6.
135. Verel I, Visser GW, Van Dongen GA, (2005). The promise of immuno-PET in
136. Wahl RL, Jacene H, Kasamon Y, Lodge MA, (2009). From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50 (Suppl. 1): 122S-150S.
137. Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, et al,. (2005). Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med 46: 114-120. (Pubitemid 43086005)
138. Wang H, Cai W, Chen K, Li ZB, Kashefi A, He L, et al,. (2007). A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging 34: 2001-2010. (Pubitemid 350212131)
139. Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA, (2008). Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res 14: 3416-3426.
140. Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, et al,. (2007). PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 34: 878-883. (Pubitemid 46798949)
141. Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, et al,. (2006). Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J Natl Cancer Inst 98: 580-598. (Pubitemid 43904842)
142. Yagle KJ, Eary JF, Tait JF, Grierson JR, Link JM, Lewellen B, et al,. (2005). Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med 46: 658-666. (Pubitemid 41716411)
143. Yang YJ, Ryu JS, Kim SY, Oh SJ, Im KC, Lee H, et al,. (2006). Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging 33: 412-419.
144. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA, (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183.
145. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al,. (1999). Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35: 1773-1782. (Pubitemid 29512308)
146. Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, et al,. (2009). PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts. Clin Cancer Res 15: 4630-4640.
147. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, et al,. (2010). Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 11: 48-54.